<DOC>
	<DOCNO>NCT01851265</DOCNO>
	<brief_summary>This 2 part study patient solid tumour . The purpose Part A measure amount olaparib breakdown product bloodstream 72 hour eat 3 different breakfast ( high calorie , regular none ) . In Part B Patients take olaparib capsule daily study assessment record 6 month ( minimum ) . Treatment continue long patient benefitting . Throughout study patient monitor side effect .</brief_summary>
	<brief_title>D081AC00001 Food Interaction With Olaparib Capsule Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Patients age ≥18 year , male female Able eat highfat breakfast within 30minute period , provide study site Histologically , appropriate , cytologically confirm malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist ECOG performance status ≤2 Normal organ bone marrow function measure within 28 day prior administration IP define protocol Participation another clinical study IP last 14 day ( long period depend defined characteristic agent use ) Patients receive systemic chemotherapy radiotherapy ( except palliative reason ) within 2 week prior study treatment ( long period depend defined characteristic agent use ) . Toxicities ( ≥CTCAE Grade 2 ) cause previous cancer therapy , exclude alopecia Patients unable fast 14 hour type I type II diabetes Patients gastric , gastrooesophageal oesophageal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>oncology , cancer , tumour , neoplasm , anticancer drug , food effect , area curve , pharmacokinetics , olaparib , solid tumour , metabolite , drug availability</keyword>
</DOC>